Chow, Po-Ming
Liu, Shih-Ping
Chuang, Yao-Chi
Lee, Kyu-Sung
Yoo, Tag Keun
Liao, Limin
Wang, Jian-ye
Liu, Ming
Sumarsono, Budiwan
Jong, Jar Jar
Funding for this research was provided by:
Astellas Pharma Singapore Pte. Ltd.
Astellas Pharma Global Development
Article History
Received: 22 February 2018
Accepted: 8 May 2018
First Online: 23 May 2018
Compliance with ethical standards
:
: All authors have acted as consultants for Astellas during a meeting to discuss the publications from this study. Po-Ming Chow has received a research grant from Astellas. Shih-Ping Liu, Yao-Chi Chuang, Kyu-Sung Lee, Limin Liao, Jian-ye Wang, and Ming Liu report no conflicts of interest. Tag Keun Yoo has received personal fees for lecturing from Hanmi Pharmaceutical and Pfizer, and has received grants and personal fees from Astellas to act as a consultant. Budiwan Sumarsono and Jar Jar Jong are employees of Astellas.
: For this type of study, formal consent is not required. As a survey-based study, institutional review board approval was not considered necessary, although the principles of the Declaration of Helsinki were followed and the study was performed in compliance with World Association for Social, Opinion, and Market Research (ESOMAR) guidelines and Good Clinical Practice. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.